Document is current

Article History

Received: 30 November 2022

Accepted: 27 January 2023

First Online: 17 February 2023

Declarations

:

: The study was approved by our Institutional Review Board (PR(IR)224/2016) and all participants consented to participated.

: VJ.G., JB.G.G. and A.L. have nothing to declare. M.T.F. has received honoraria as a consultant or speaker for Allergan-Abbvie, Almirall, Chiesi, Eli Lilly, Novartis and Teva. A.A. has received honoraria from Allergan-Abbvie, Novartis, Chiesi. E.C. reports no diclosures. P.P.R. has received honoraria as a consultant and speaker for: AbbVie, Amgen, Biohaven, Chiesi, Eli Lilly, Lundbeck, Medscape, Novartis, Pfizer and Teva. Her research group has received research grants from AbbVie, Novartis and Teva; and, has received funding for clinical trials from Alder, AbbVie, Amgen, Biohaven, Electrocore, Eli Lilly, Lundbeck, Novartis and Teva. She is the Honorary Secretary of the International Headache Society. She is in the editorial board of Revista de Neurologia, associate editor for Cephalalgia, Headache, Neurologia, Frontiers of Neurology. She is a member of the Clinical Trials Guidelines Committee and Scientific Committee of the International Headache Society. She has edited the Guidelines for the Diagnosis and Treatment of Headache of the Spanish Neurological Society. She is the founder of. Pozo-Rosich P does not own stocks from any pharmaceutical company.